FDA drug reviewers said in briefing documents Monday that they were not confident that the risks of vision loss associated with Ovation Pharmaceuticals Inc.'s investigational antiepileptic drug Sabril (vigabatrin) could be mitigated sufficiently by a safety plan proposed by the Deerfield, Ill.-based firm. (BioWorld Today) Read More
